



DAILY MARKET WATCH

Market Commentary

BIST 100 closed the previous session down 0.78% at 11,036.82, with trading volumes reaching their highest level since late October. Despite the negative performance of the BIST100, the banking index carried on to rise and outperformed others after the inflation data released. The benchmark is expected to open cautiously, with investors focusing on today's heavy domestic data flow and global risk sentiment.

In Turkey, markets will follow a dense set of releases. At 14:00, BRSA will publish weekly sector data, followed by the CBRT's Real Effective Exchange Rate and weekly monetary statistics at 14:30. Turkstat(TUIK) will announce seasonally adjusted CPI at 16:00, and the CBRT will release its Monthly Price Developments Report at 18:00. Headlines remain centered on inflation dynamics, TL performance, and policy communication from CBRT officials.

Globally, Eurozone retail sales at 13:00 will guide sentiment, while the U.S. agenda includes weekly jobless claims at 16:30 and natural gas inventory data at 18:30. ADP employment unexpectedly fell by 32,000—versus a 5,000 increase expected—pressuring the dollar index. U.S. industrial production rose 0.1% as forecast, while capacity utilization disappointed at 75.9%. PMIs in the U.S. and Europe presented a mixed picture: Eurozone services activity improved, while Spain came in weaker than expected.

The Turkish lira continued to weaken against majors, with GBP/TRY at 56.70 and EUR/TRY surpassing 49.59 to fresh all-time highs. USD/TRY at 42.47 in the early trading quotes.

Market Figures Table	BIST Figures (TRY)			MSCI Figures		Bond Market		Money Market			Market Est.			
	BIST-100	Trading Vol.	Foreign%	EM	Turkey	Bench.	10Yr Bond	US\$/TRY	EUR/TRY	Basket	Is Inv.Est.	P/E		
Close	11,037	245,608	36.07	1374	286	37.95	31.24	42.4465	49.4499	45.8630	2025	12.07%		
Daily Δ	▼ -0.8%	▲ 20.8%	-0.2 bps	▲ 0.0%	▼ -0.8%	-49 bps	-0.09 bps	▲ 0.0%	▲ 0.4%	▲ 0.0%	2026	9.08%		
1M Δ	▼ -0.2%	▲ 3.3%	-0.1 bps	▼ -2.0%	▼ -1.7%	-208 bps	-0.57 bps	▲ 0.9%	▲ 0.4%	▲ 0.1%	2027	7.70%		
BIST-100 Best / Worst Performers & BIST-100 Top 5 by Trading Volume (Daily Δ)														
Best 5 Performance (%)	CWENE		8%	RALYH		6%	EFOR		6%	GRTHO		5%	VAKBN	4%
Worst 5 Performance (%)	DSTKF		-10%	BIMAS		-4%	PASEU		-3%	MGROS		-3%	DOAS	-3%
Top 5 by Volume (TRY mn)	AKBNK		19330	ISCTR		17923	YKBNK		15641	GARAN		11084	THYAO	10014

MLP Sağlık Hizmetleri

Price (TL) : 320.75 - T.P.(TL) : 514.51 - Mcap.mn.(TL) : 61267 - 3M ADV(mn\$) : 6.32

MPARK TI Equity- Rec.:BUY Upside%: 60.41 Analyst: eakalan@isyatirim.com.tr **MLP Care completed the transfer process of a company holding, a Özel Gaziosmanpaşa Hospital license and a dialysis center in Istanbul.**

MLP Care announced that its ongoing negotiations with Bileşim Turizm İnşaat Sanayi ve Ticaret A.Ş. have been finalized and the share transfer has been completed. With the completion of the transaction, a hospital license with a capacity of 403 beds and the Gaziosmanpaşa Dialysis Center with 84 devices have been incorporated into MLP Care's portfolio. No information was disclosed regarding the transaction value. Neutral.



This report has been prepared by İş Yatırım Menkul Değerler A.Ş. (“İş Investment” or “Company”) solely for the information of clients of İş Investment. Opinions and estimates contained in this material are not under the scope of investment advisory services. Investment advisory services are given according to the investment advisory contract, signed between the intermediary institutions, portfolio management companies, investment banks and the clients. Opinions and recommendations contained in this report reflect the personal views of the analysts who supplied them. The investments discussed or recommended in this report may involve significant risk, may be illiquid and may not be suitable for all investors. Investors must make their decisions based on their specific investment objectives and financial positions and with the assistance of independent advisors, as they believe necessary.

The prices, data and information contained herein cannot be guaranteed to be complete and accurate; the content is subject to change without notice. The information presented in this report has been obtained from public institutions, such as Borsa İstanbul A.Ş., Capital Market Board of Turkey (CMB), , Central Bank of the Republic of Turkey (CBT); various media institutions, and other sources believed to be reliable. İş Investment is not responsible for any possible errors that may arise due to the use of these sources.

This report and the information contained within it include certain forward-looking assumptions, but these assumptions do not guarantee any definite or absolute outcomes. The information in this report may require verification, completion, or modification. In this regard, Company reserves the right to make any necessary changes at any time without notice or permission to any party.

All information in these pages remains the property of İş Investment and as such may not be disseminated, copied, altered or changed in any way, nor may this information be printed for distribution purposes or forwarded as electronic attachments without the prior written permission of İş Investment. (www.isyatirim.com.tr)

This report does not constitute an offer, invitation, or encouragement to make an investment or to purchase or acquire any securities, nor does it form the basis of any legal agreement or contract. Investors are required to conduct their own research on all topics covered here and make their investment decisions based on the findings of their research. The Company, its Board Members, executives, or employees do not accept any responsibility or liability for any damages arising from the use of the content of this presentation.

“Rating Disclosure: İş Investment’s ratings for the listed stocks are Outperform, Market Perform and Underperform, which are all benchmarked with the expected return of the Borsa İstanbul A.Ş. (“BIST 100”). All these ratings are independently assigned by İş Investment equity analysts based on company’s estimates which pertain to future earnings, cash flow and balance sheet of the company. Additionally, analysts may put the stocks Under Review on a temporary basis if conditions do not allow or restrict to make a proper assesment of the company. İş Investment Stock Recommendation Methodology,

Upside Potential >25% : BUY
10% < Upside potential < 25% : HOLD
Upside potential < 10% : SELL
+/- 5% Analyst judgment at each boundary.